Key facts
- It has raised $1.5M across 1 recorded rounds; the latest was Seed Round ($1.0M) in Feb 2026.
- Notable investors include MintPharma Capital.
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for NOXX Therapeutics
Funding rounds
1 roundsAbout NOXX Therapeutics
Developer of monoclonal antibodies and conjugates intended to target a clinically validated pathway responsible for tumor-induced immune suppression. The company offers antibody and conjugate engineering capabilities, enabling oncology researchers and clinicians to address immune suppression and improve therapeutic outcomes.
- Sector
- Healthcare
- HQ
- Boca Raton, FL, United States
- Founded
- 2023
- Employees
- 2
- Ownership
- Privately Held (backing)
NOXX Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NOXX Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NOXX Therapeutics in its N-PORT filings yet. We sweep new filings monthly.